LabyRx Immuno-Oncology
- Biotech or pharma, therapeutic R&D
Clinical-stage immuno-oncology company. Platforms: 1) In Phase II clinical trial with an active immunotherapy treatment against 40% of all cancers (adenocarcinomas); 2) Antibody-based treatments and diagnostics in pre-clinical stage.
Results of our clinical trial has warranted US FDA application for "Breakthrough"designation. Seeking Series A round and/or pre-clinical for the antibody-based platform.
Open to M&A, spin-off or full IP acquisition or collaborative development (e.g., CAR-T/M, antibodies, etc.) as a true joint venture (not contract work).
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}